Gyre Therapeutics, Inc.
$6.34
The Read: 7% following a well-executed equity raise, but dropped nearly 10% again when China’s NMPA delayed F351 approval and Q1 revenue missed estimates.
Price
Overlays
Panel
GYRE
Hover to view data
No Data
By creating an account you agree to our Terms of Service and Privacy Policy.
$6.34
The Read: 7% following a well-executed equity raise, but dropped nearly 10% again when China’s NMPA delayed F351 approval and Q1 revenue missed estimates.
No Data